Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

(2013) Gunther Zimmermann et al.   NATURE

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

(2013) D. M. Molina et al.   SCIENCE

The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence

(2012) O. Aksoy et al.   GENES & DEVELOPMENT

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras

(2011) J. Xu et al.   BLOOD

Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing

(2011) Oleg Fedorov et al.   CHEMISTRY & BIOLOGY

Crystal structure of human MTH1 and the 8-oxo-dGMP product complex

(2011) Linda M. Svensson et al.   FEBS LETTERS

An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance

(2011) J. Zuber et al.   GENES & DEVELOPMENT

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

(2011) J. Jean Cui et al.   JOURNAL OF MEDICINAL CHEMISTRY

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

(2010) David E. Gerber et al.   CANCER CELL

Small-molecule inhibition of APT1 affects Ras localization and signaling

(2010) Frank J Dekker et al.   Nature Chemical Biology

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

(2010) James E. Butrynski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence

(2010) P Rai et al.   ONCOGENE

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence

(2009) P. Rai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Two distinct pathways of cell death triggered by oxidative damage to nuclear and mitochondrial DNAs

(2008) Sugako Oka et al.   EMBO JOURNAL